Liver Diseases  >>  IDX 184  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IDX 184 / Merck (MSD)
NCT01011166: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Completed
2
81
US
IDX184, Placebo, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV)
Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
07/10
07/10
NCT01371604 / 2011-001878-25: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Checkmark IDX-184+/-(P+R)
Jun 2012 - Jun 2012: IDX-184+/-(P+R)
Completed
2
68
US
IDX184, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV), Placebo
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
03/13
10/14
NCT00807001 / 2008-005558-19: Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Completed
1/2
41
US, RoW
IDX184
Merck Sharp & Dohme LLC
Chronic Hepatitis C (HCV)
07/09
07/09

Download Options